ReviewCancer treatment reviews2019
Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.
Review in Cancer treatment reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.American journal of hematology · 2025Trial
- Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.Journal of geriatric oncology · 2022Trial
- Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies.Current oncology reports · 2024Review
- Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.Journal of personalized medicine · 2023Article
- Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- Precision Medicine in Myeloid Malignancies: Hype or Hope?Current hematologic malignancy reports · 2022Review
- Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?Future oncology (London, England) · 2022Article
- Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.HemaSphere · 2021Review
- Development and validation of the Therapy Preference Scale to understand patients´ systemic cancer treatment preferences.Future oncology (London, England) · 2021Article
- Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.Clinical lymphoma, myeloma & leukemia · 2020Article
- Novel Treatment Paradigms in Acute Myeloid Leukemia.Clinical pharmacology and therapeutics · 2020Review
- Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.Clinical lymphoma, myeloma & leukemia · 2020Article
- Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.Blood advances · 2020Article
- Treatment Strategies for Therapy-related Acute Myeloid Leukemia.Clinical lymphoma, myeloma & leukemia · 2020Review
- Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities.Future oncology (London, England) · 2019Article
- Comprehensive Geriatric Assessment as a Versatile Tool to Enhance the Care of the Older Person Diagnosed with Cancer.Geriatrics (Basel, Switzerland) · 2019Review
- Allogeneic Hematopoietic Cell Transplantation in Younger Patients With Acute Myeloid Leukemia.Journal of oncology practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from "one size fits all" approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.